Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses

British Journal of Dermatology

Volumn 171, Issue 6, 2014, Pages 1307-1317

  Keith, P J ^a   Wetter, D A ^a   Wilson, J W ^a   Lehman, J S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; COMMUNICABLE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMOLYSIS BULLOSA ACQUISITA; EVIDENCE BASED PRACTICE; FECES ANALYSIS; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; PATIENT RISK; PEMPHIGUS VULGARIS; PRACTICE GUIDELINE; REVIEW; SCREENING TEST; STRONGYLOIDIASIS; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUBERCULOSIS; VIRUS REACTIVATION; WESTERN BLOTTING; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASE CONTROL; EVIDENCE BASED MEDICINE; FEMALE; INFECTION; LABORATORY TEST; MALE; PROCEDURES; RISK FACTOR; SKIN DISEASES, VESICULOBULLOUS;

AUTOIMMUNE DISEASES; CLINICAL LABORATORY TECHNIQUES; COMMUNICABLE DISEASE CONTROL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MALE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SKIN DISEASES, VESICULOBULLOUS;

EID: 84919459654     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13355     Document Type: Review

References (87)

1. Lehman JS, Murrell DF, Camilleri MJ, Kalaaji AN,. Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. Dermatol Clin 2011; 29: 591-8.
2. Langan SM, Smeeth L, Hubbard R, et al,. Bullous pemphigoid and pemphigus vulgaris: incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
3. Motaparthi K, Stanisic V, Van Voorhees AS, et al,. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol 2014; 70: 178-86.
4. Barrick BJ, Lohse CM, Lehman JS,. Specific causes of death in patients with bullous pemphigoid as measured by death certificate data: a retrospective cohort study. Int J Dermatol 2013 (in press).
5. Stern RS, Huibregtse A,. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol 2011; 131: 1159-66.
6. Lehman JS, Khunger M, Lohse CM,. Infection in autoimmune bullous diseases: a retrospective comparative study. J Dermatol 2013; 40: 613-19.
7. Centers for Disease Control and Prevention. Vaccine Recommendations of the Advisory Committee for Immunization Practices (ACIP). CDC, 2014. Available at: http://www.cdc.gov/vaccines/hcp/acip-recs/index.html (accessed on 6 November 2014).
8. Weinbaum CM, Williams I, Mast EE, et al,. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20.
9. US Department of Health and Human Services; Centers for Disease Control and Prevention. Publication No. 21-1076. The ABCs of Hepatitis. CDC, 2012. Available at: http://www.cdc.gov/hepatitis/resources/professionals/pdfs/abctable.pdf (accessed on 6 November 2014).
10. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47: 1-39.
11. Moyer VA,; US Preventive Services Task Force. Screening for HIV: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 51-60.
12. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49: 1-51.
13. Centers for Disease Control and Prevention; Division of Tuberculosis Elimination. Tuberculosis (TB): Basic TB Facts, Risk Factors. CDC, 2012. Available at: http://www.cdc.gov/tb/topic/basics/default.htm (accessed on 6 November 2014).
14. Siddiqui AA, Berk SL,. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33: 1040-7.
15. Centers for Disease Control and Prevention; Division of Parasitic Diseases and Malaria. Strongyloides: Epidemiology and Risk Factors. CDC, 2012. Available at: http://www.cdc.gov/parasites/strongyloides/epi.html (accessed on 6 November 2014).
16. Genta RM,. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis 1989; 11: 755-67.
17. Sorvillo F, Mori K, Sewake W, Fishman L,. Sexual transmission of Strongyloides stercoralis among homosexual men. Br J Vener Dis 1983; 59: 342.
18. Hayward AR, Herberger M,. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987; 7: 174-8.
19. Centers for Disease Control and Prevention. Prevalence of Hepatitis B Surface Antigen. CDC, 2012. Available at: http://wwwnc.cdc.gov/travel/pdf/yellowbook-2012-map-03-04-prevalence-chronic-infection-hepatitis-b.pdf (accessed on 6 November 2014).
20. Hoofnagle JH,. Reactivation of hepatitis B. Hepatology 2009; 49: S156-65.
21. Aksoy S, Harputluoglu H, Kilickap S, et al,. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307-12.
22. Ito S, Nakazono K, Murasawa A, et al,. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 339-42.
23. Flowers MA, Heathcote J, Wanless IR, et al,. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112: 381-2.
24. Morisco F, Castiglione F, Rispo A, et al,. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011; 43: S40-8.
25. Yang CH, Wu TS, Chiu CT,. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007; 157: 587-90.
26. Inadomi T, Saito T, Kaneko M, et al,. Bullous pemphigoid in an HB virus carrier: interaction between corticosteroids and HB virus. J Dermatol 1997; 24: 179-83.
27. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
28. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection [published correction appears in J Hepatol 2013; 58:201]. J Hepatol 2012; 57: 167-85.
29. Meggitt SJ, Anstey AV, Mohd Mustapa MF, et al,. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011; 165: 711-34.
30. Saag KG, Teng GG, Patkar NM, et al,. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
31. Singh JA, Furst DE, Bharat A, et al,. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
32. Rahier JF, Ben-Horin S, Chowers Y, et al,. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
33. Fischer SA, Avery RK,; AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9: S7-18.
34. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients [published correction appears in MMWR Recomm Rep 2004; 53:396]. MMWR Recomm Rep 2000; 49: 1-125, CE1-7.
35. Smith BD, Morgan RL, Beckett GA, et al,. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965 [published correction appears in MMWR Recomm Rep 2012; 61:886]. MMWR Recomm Rep 2012; 61: 1-32.
36. Alter MJ, Kuhnert WL, Finelli L,; Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep 2003; 52: 1-13.
37. Moyer VA,; US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 349-57.
38. Ghany MG, Strader DB, Thomas DL, et al,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
39. Qaseem A, Snow V, Shekelle P, et al,. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med 2009; 150: 125-31.
40. Centers for Disease Control and Prevention; Division of Parasitic Diseases and Malaria. Strongyloides: Prevention and Control. CDC, 2012. Available at: http://www.cdc.gov/parasites/strongyloides/prevent.html/ (accessed on 6 November 2014).
41. Centers for Disease Control and Prevention; National Center for Immunization and Respiratory Diseases; Division of Viral Diseases. Chickenpox (Varicella): Assessing Immunity in Varicella. CDC, 2013. Available at: http://www.cdc.gov/chickenpox/hcp/immunity.html (accessed on 6 November 2014).
42. Harpaz R, Ortega-Sanchez IR, Seward JF, et al,. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57: 1-30.
43. Martin ST, Cardwell SM, Nailor MD, Gabardi S,. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation. Am J Transplant 2014; 1: 788-96.
44. Cianchini G, Lupi F, Masini C, et al,. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol 2012; 67: 617-22.
45. Shetty S, Ahmed AR,. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature. J Drugs Dermatol 2013; 12: 672-7.
46. Calabrese LH, Zein NN, Vassilopoulos D,. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-9.
47. Sagnelli E, Pisaturo M, Sagnelli C, Coppola N,. Rituximab-based treatment, HCV replication, and hepatic flares. Clin Dev Immunol 2012; 2012: 945950.
48. Shook BA, Wells MJ, Rapini RP, Cobos E,. Epidermolysis bullosa acquisita occurring in 2 patients with hepatitis C. J Am Acad Dermatol 2006; 54: 888-91.
49. Chen TJ, Lai PC, Yang LC, et al,. Bullous pemphigoid in a renal transplant recipient: a case report and review of the literature. Am J Clin Dermatol 2009; 10: 197-200.
50. Lateef A, Packles MR, White SM, et al,. Pemphigus vegetans in association with human immunodeficiency virus. Int J Dermatol 1999; 38: 778-81.
51. Mahe A, Flageul B, Prost C, et al,. Pemphigus vegetans in an HIV-1-infected man. Clin Exp Dermatol 1994; 19: 447.
52. Splaver A, Silos S, Lowell B, et al,. Case report: pemphigus vulgaris in a patient infected with HIV. AIDS Patient Care STDS 2000; 14: 295-6.
53. Marfatia YS, Patel S, Makrandi S, Sharma P,. Human immunodeficiency virus and pemphigus vulgaris: an interesting association. Indian J Dermatol Venereol Leprol 2007; 73: 354-5.
54. Hodgson TA, Fidler SJ, Speight PM, et al,. Oral pemphigus vulgaris associated with HIV infection. J Am Acad Dermatol 2003; 49: 313-15.
55. Capizzi R, Marasca G, De Luca A, et al,. Pemphigus vulgaris in a human-immunodeficiency-virus-infected patient. Dermatology 1998; 197: 97-8.
56. Levy PM, Balavoine JF, Salomon D, et al,. Ritodrine-responsive bullous pemphigoid in a patient with AIDS-related complex. Br J Dermatol 1986; 114: 635-6.
57. Bull RH, Fallowfield ME, Marsden RA,. Autoimmune blistering diseases associated with HIV infection. Clin Exp Dermatol 1994; 19: 47-50.
58. Chou K, Kauh YC, Jacoby RA, Webster GF,. Autoimmune bullous disease in a patient with HIV infection. J Am Acad Dermatol 1991; 24: 1022-3.
59. Lish KM, Washenik K, Yancey KB, et al,. Anti-epiligrin cicatricial pemphigoid in a patient with HIV. J Am Acad Dermatol 1997; 36: 486-8.
60. Centers for Disease Control and Prevention. Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm: United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2013; 62: 489-94.
61. Sahn SA, Lakshminarayan S,. Tuberculosis after corticosteroid therapy. Br J Dis Chest 1976; 70: 195-205.
62. Millar JW, Horne NW,. Tuberculosis in immunosuppressed patients. Lancet 1979; 1: 1176-8.
63. Kawabata E, Morita K, Matsuyoshi N, et al,. Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. J Dermatol 1995; 22: 582-6.
64. Nanda A, Nanda M, Dvorak R, et al,. Bullous pemphigoid (BP) in an infant complicated by tuberculous meningoencephalitis. Int J Dermatol 2007; 46: 964-6.
65. Gurcan HM, Ahmed AR,. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009; 161: 723-31.
66. Huang YH, Kuo CF, Chen YH, Yang YW,. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. J Invest Dermatol 2012; 132: 92-7.
67. Rogers S, Larkin C, McDonald GS, et al,. Epidermolysis bullosa acquisita with pulmonary tuberculosis: a case report. Clin Exp Dermatol 1983; 8: 311-18.
68. Chan YC, Yosipovitch G,. Suggested guidelines for screening and management of tuberculosis in patients taking oral glucocorticoids: an important but often neglected issue. J Am Acad Dermatol 2003; 49: 91-5.
69. Centers for Disease Control and Prevention; Division of Tuberculosis Elimination. Tuberculosis (TB): Testing and Diagnosis. CDC, 2013. Available at: http://www.cdc.gov/tb/topic/testing/ (accessed on 6 November 2014).
70. Lam CS, Tong MK, Chan KM, Siu YP,. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006; 25: 14-18.
71. Roxby AC, Gottlieb GS, Limaye AP,. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49: 1411-23.
72. Centers for Disease Control and Prevention. Transmission of Strongyloides stercoralis through transplantation of solid organs: Pennsylvania, 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 264-6.
73. Mejia R, Nutman TB,. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 2012; 25: 458-63.
74. Azira NM, Zeehaida M,. Strongyloides stercoralis hyperinfection in a diabetic patient: case report. Trop Biomed 2010; 27: 115-19.
75. Reddy IS, Swarnalata G,. Fatal disseminated strongyloidiasis in patients on immunosuppressive therapy: report of two cases. Indian J Dermatol Venereol Leprol 2005; 71: 38-40.
76. Sarubbi FA,. Hyperinfection with Strongyloides during treatment of pemphigus vulgaris. Arch Dermatol 1987; 123: 864-5.
77. Walker SL, Mann TAN,. Strongyloidiasis complicating immunosuppression for pemphigus vulgaris [letter]. Br J Dermatol 2013; 69: 1363-4.
78. Vitiello M, Shelling M, Camacho I, et al,. Fatal cutaneous strongyloidiasis as a side effect of pemphigus foliaceus treatment with mycophenolate mofetil. J Drugs Dermatol 2011; 10: 418-21.
79. Centers for Disease Control and Prevention; Division of Parasitic Diseases and Malaria. Strongyloides: Resources for Health Professionals. CDC, 2012. Available at: http://www.cdc.gov/parasites/strongyloides/health-professionals/ (accessed on 6 November 2014).
80. Cartwright CP,. Utility of multiple-stool-specimen ova and parasite examinations in a high-prevalence setting. J Clin Microbiol 1999; 37: 2408-11.
81. van Doorn HR, Koelewijn R, Hofwegen H, et al,. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 2007; 45: 438-42.
82. Stevenson ML, Levitt JO,. Acute zoster in known pemphigus vulgaris and bullous pemphigoid: avoiding the 'disease flare' trap. J Am Acad Dermatol 2011; 64: e125-6.
83. Marzano AV, Dassoni F, Caputo R,. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat 2006; 17: 370-6.
84. Arvin AM,. Varicella-zoster virus. Clin Microbiol Rev 1996; 9: 361-81.
85. Breuer J, Schmid DS, Gershon AA,. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis 2008; 197: S147-51.
86. Kimberlin DW, Whitley RJ,. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356: 1338-43.
87. Arness T, Pedersen R, Dierkhising R, et al,. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis 2008; 10: 260-8.